Wild-type Transthyretin Amyloid Myopathy With an Inclusion Body Myositis Phenotype.
Journal
Journal of clinical neuromuscular disease
ISSN: 1537-1611
Titre abrégé: J Clin Neuromuscul Dis
Pays: United States
ID NLM: 100887391
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
entrez:
25
8
2020
pubmed:
25
8
2020
medline:
7
7
2021
Statut:
ppublish
Résumé
Senile systemic amyloidosis (SSA), or wild-type transthyretin (wtATTR) amyloidosis, is associated most commonly with cardiomyopathy and carpal tunnel syndrome. SSA-associated skeletal myopathy is rare. We describe the case of a patient with SSA who exhibited asymmetric quadriceps and finger flexor weakness, a phenotype usually seen in inclusion body myositis.
Identifiants
pubmed: 32833725
doi: 10.1097/CND.0000000000000288
pii: 00131402-202009000-00007
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
53-57Références
Spuler S, Emslie-Smith A, Engel AG. Amyloid myopathy: an underdiagnosed entity. Ann Neurol. 1998;43:719–728.
Amato AA, Barohn RJ. Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry. 2009;80:1186–1193.
Weihl CC, Pestronk A, Kimonis VE. Valosin-containing protein disease: inclusion body myopathy with Paget's disease of the bone and frontotemporal dementia. Neuromuscul Disord. 2009;19:308–315.
Selcen D. Myofibrillar myopathies. Neuromuscul Disord. 2011;21:161–171.
Liewluck T, Milone M. Characterization of isolated amyloid myopathy. Eur J Neurol. 2017;24:1437–1445.
Muchtar E, Buadi FK, Dispenzieri A, et al. Immunoglobulin light-chain amyloidosis: from basics to new developments in diagnosis, prognosis and therapy. Acta Haematol. 2016;135:172–190.
Yamashita T, Ando Y, Katsuragi S, et al. Muscular amyloid angiopathy with amyloidgenic transthyretin Ser50Ile and Tyr114Cys. Muscle Nerve. 2005;31:41–45.
Yamada M, Tsukagoshi H, Hatakeyama S. Skeletal muscle amyloid deposition in AL- (primary or myeloma-associated), AA- (secondary), and prealbumin-type amyloidosis. J Neurol Sci. 1988;85:223–232.
Tanabe H, Maki Y, Urabe S, et al. Myopathy in a patient with systemic AA amyloidosis possibly induced by psoriasis vulgaris: an autopsy case. Muscle Nerve. 2015;52:1113–1117.
Sekijima Y, Uchiyama S, Tojo KK, et al. High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly. Hum Pathol. 2011;42:1785–1791.
Cornwell GG, Murdoch WL, Kyle RA, et al. Frequency and distribution of senile cardiovascular amyloid. Am J Med. 1983;75:618–623.
Johansson B, Westermark P. Senile systemic amyloidosis: a clinico-pathological study of twelve patients with massive amyloid infiltration. Int J Cardiol. 1991;32:83–92.
Sueyoshi T, Ueda M, Sei A, et al. Spinal multifocal amyloidosis derived from wild-type transthyretin. Amyloid. 2011;18:165–168.
Pitkänen P, Westermark P, Cornwell GG. Senile systemic amyloidosis. Am J Pathol. 1984;117:391–399.
Lam L, Margeta M, Layzer R. Amyloid polyneuropathy caused by wild-type transthyretin. Muscle Nerve. 2015;52:146–149.
Rezania K, Pytel P, Smit LJ, et al. Systemic transthyretin amyloidosis in a patient with bent spine syndrome. Amyloid. 2013;20:131–134.
Jennekens FGI, Wokke JHJ. Proximal weakness of the extremities as main feature of amyloid myopathy. J Neurol Neurosurg Psychiatry. 1987;50:1353–1358.
Nadkarni N, Freimer M, Mendell JR. Amyloidosis causing a progressive myopathy. Muscle Nerve. 1995;18:1016–1018.
Chapin JE, Kornfeld M, Harris A. Amyloid myopathy: characteristic features of a still underdiagnosed disease. Muscle Nerve. 2005;31:266–272.
Whitaker JN, Hashimoto K, Quinones M. Skeletal muscle pseudohypertrophy in primary amyloidosis. Neurology. 1977;27:47–54.
Elomaa I, Ekblom P, Somer T. Amyloid-associated muscle pseudohypertrophy and multiple myeloma in a man with hypernephroma. Acta Med Scand. 1983;214:87–91.
Gertz MA, Kyle RA. Myopathy in primary systemic amyloidosis. J Neurol Neurosurg Psychiatry. 1996;60:655–660.
Sibelt LAG, Lokhorst HM, van de Kerkhof PCM, et al. J Eur Acad Dermatol Venereol. 2007;21:986–988.
Streeten EA, de la Monte SM, Kennedy TP. Amyloid infiltration of the diaphragm as a cause of respiratory failure. Chest. 1986;89:760–762.
Santiago RM, Scharnhorst D, Ratkin G, et al. Respiratory muscle weakness and ventilatory failure in AL amyloidosis with muscular pseudohypertrophy. Am J Med. 1987;83:175–178.
Ashe J, Borel CO, Hart G, et al. Amyloid myopathy presenting with respiratory failure. J Neurol Neurosurg Psychiatry. 1992;55:162–165.
Simmons Z, Specht CS. The neuromuscular manifestations of amyloidosis. J Clin Neuromuscul Dis. 2010;11:145–157.
Hamasaki A, Dimachkie M, Pasnoor M, et al. Amyloid myopathy as an inclusion body myositis mimic (P2.127). Neurology. 2017;88.
Jacobson R, Gallagher G, Feldman E. Amyloid myopathy presenting with dysphagia and an inclusion body myositis phenotype (P2.119). Neurology. 2017;88.
Tuomaala H, Kärppä M, Tuominen H, et al. Amyloid Myopathy: A Diagnostic Challenge. Neurology International, PAGEPress Publications; 2009.
Grogan M, Witteles R, Shah J, et al. Efficacy of tafamidis in patients with hereditary or wild-type transthyretin amyloid cardiomyopathy: further results from the ATTR-ACT trial. J Heart Lung Transplant. 2019;38:S204.